Catalyst Oncology

A late-stage clinical trial of the Pfizer Inc. cancer drug Sutent has been halted early after researchers determined the drug was no better at fighting advanced colon cancer than standard chemotherapy.Just last month, Pfizer was praising Sutent’s performance in a study of the drug’s effectiveness in slowing a rare but potentially life-threatening form of pancreatic cancer. According to those findings, Sutent more than doubled the amount of time cancer patients lived progression-free. The clinica

Go here to read the rest: 
Pfizer Cancer Drug Sutent Fails Test for Advanced Colon Cancer